A proteome-wide genetic investigation identifies several sars-cov-2-exploited host targets of clinical relevance

dc.contributor.authorKarim, Mohd A.
dc.contributor.authorShilts, Jarrod
dc.contributor.authorSchwartzentruber, Jeremy
dc.contributor.authorHayhurst, James
dc.contributor.authorBuniello, Annalisa
dc.contributor.authorMohammed, Elmutaz Shaikho Elhaj
dc.contributor.authorZheng, Jie
dc.contributor.authorHolmes, Michael V.
dc.contributor.authorOchoa, David
dc.contributor.authorCarmona, Miguel
dc.contributor.authorMaranville, Joseph
dc.contributor.authorGaunt, Tom R.
dc.contributor.authorEmilsson, Valur
dc.contributor.authorGuðnason, Vilmundur G.
dc.contributor.authorMcDonagh, Ellen M.
dc.contributor.authorWright, Gavin J.
dc.contributor.authorGhoussaini, Maya
dc.contributor.authorDunham, Ian
dc.contributor.departmentFaculty of Medicine
dc.date.accessioned2025-11-20T08:26:46Z
dc.date.available2025-11-20T08:26:46Z
dc.date.issued2021-08-17
dc.descriptionMAK, JSc, JH, AB, DO, MC, EMM, MG, ID were funded by Open Targets. J.Z. and T.R.G were funded by the UK Medical Research Council Integrative Epidemiology Unit (MC_UU_00011/4). JSh and GJW were funded by the Wellcome Trust Grant 206194. This research was funded in part by the Wellcome Trust [Grant 206194]. For the purpose of open access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission. Publisher Copyright: © 2021, eLife Sciences Publications Ltd. All rights reserved.en
dc.description.abstractBackground: The virus SARS-CoV-2 can exploit biological vulnerabilities (e.g. host proteins) in susceptible hosts that predispose to the development of severe COVID-19. Methods: To identify host proteins that may contribute to the risk of severe COVID-19, we undertook proteome-wide genetic colocalisation tests, and polygenic (pan) and cis-Mendelian randomisation analyses leveraging publicly available protein and COVID-19 datasets. Results: Our analytic approach identified several known targets (e.g. ABO, OAS1), but also nominated new proteins such as soluble Fas (colocalisation probability >0.9, p=1 × 10 -4), implicating Fas-mediated apoptosis as a potential target for COVID-19 risk. The polygenic (pan) and cis-Mendelian randomisation analyses showed consistent associations of genetically predicted ABO protein with several COVID-19 phenotypes. The ABO signal is highly pleiotropic, and a look-up of proteins associated with the ABO signal revealed that the strongest association was with soluble CD209. We demonstrated experimentally that CD209 directly interacts with the spike protein of SARS-CoV-2, suggesting a mechanism that could explain the ABO association with COVID-19. Conclusions: Our work provides a prioritised list of host targets potentially exploited by SARS-CoV-2 and is a precursor for further research on CD209 and FAS as therapeutically tractable targets for COVID-19. Funding: MAK, JSc, JH, AB, DO, MC, EMM, MG, ID were funded by Open Targets. J.Z. and T.R.G were funded by the UK Medical Research Council Integrative Epidemiology Unit (MC_UU_00011/4). JSh and GJW were funded by the Wellcome Trust Grant 206194. This research was funded in part by the Wellcome Trust [Grant 206194]. For the purpose of open access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission.en
dc.description.versionPeer revieweden
dc.format.extent1671634
dc.format.extent
dc.identifier.citationKarim, M A, Shilts, J, Schwartzentruber, J, Hayhurst, J, Buniello, A, Mohammed, E S E, Zheng, J, Holmes, M V, Ochoa, D, Carmona, M, Maranville, J, Gaunt, T R, Emilsson, V, Guðnason, V G, McDonagh, E M, Wright, G J, Ghoussaini, M & Dunham, I 2021, 'A proteome-wide genetic investigation identifies several sars-cov-2-exploited host targets of clinical relevance', eLife, vol. 10, e69719. https://doi.org/10.7554/eLife.69719en
dc.identifier.doi10.7554/eLife.69719
dc.identifier.issn2050-084X
dc.identifier.other39164932
dc.identifier.otherc9b5a94e-b94e-4ab1-bd8b-ed3998b5fe2e
dc.identifier.other85114098773
dc.identifier.other34402426
dc.identifier.urihttps://hdl.handle.net/20.500.11815/6396
dc.language.isoen
dc.relation.ispartofserieseLife; 10()en
dc.relation.urlhttps://www.scopus.com/pages/publications/85114098773en
dc.rightsinfo:eu-repo/semantics/openAccessen
dc.subjectCovid-19en
dc.subjectGenome associationen
dc.subjectSARS-CoV-2en
dc.subjectSeverity of Illness Indexen
dc.subjectGenome-Wide Association Studyen
dc.subjectScavenger Receptors, Class A/geneticsen
dc.subjectCell Adhesion Moleculesen
dc.subjectHumansen
dc.subjectLectins, C-Typeen
dc.subjectfas Receptor/geneticsen
dc.subjectProteomeen
dc.subjectReceptors, Cell Surfaceen
dc.subject2',5'-Oligoadenylate Synthetase/geneticsen
dc.subjectSARS-CoV-2/physiologyen
dc.subjectCOVID-19/geneticsen
dc.subjectGeneral Biochemistry,Genetics and Molecular Biologyen
dc.subjectGeneral Immunology and Microbiologyen
dc.subjectGeneral Neuroscienceen
dc.subjectSDG 3 - Good Health and Well-beingen
dc.titleA proteome-wide genetic investigation identifies several sars-cov-2-exploited host targets of clinical relevanceen
dc.type/dk/atira/pure/researchoutput/researchoutputtypes/contributiontojournal/articleen

Skrár

Original bundle

Niðurstöður 1 - 1 af 1
Nafn:
elife_69719_v2.pdf
Stærð:
1.59 MB
Snið:
Adobe Portable Document Format

Undirflokkur